Anixa Biosciences(US:ANIX)2025-03-11 20:20Revenue Performance - Revenue for the three months ended January 31, 2025, was $0, consistent with the same period in 2024[81]. - The company does not expect to begin generating revenue from its current therapy or vaccine programs in the near term[82]. Expenses - Research and development expenses increased by approximately $203,000 to approximately $1,552,000 for the three months ended January 31, 2025, compared to approximately $1,349,000 in the same period in 2024[84]. - General and administrative expenses decreased by approximately $426,000 to approximately $1,834,000 for the three months ended January 31, 2025, from approximately $2,260,000 in the same period in 2024[86]. - Interest income decreased by approximately $146,000 to approximately $173,000 for the three months ended January 31, 2025, from approximately $319,000 in the same period in 2024[87]. Assets and Cash Flow - Total current assets decreased by approximately $2,676,000 to approximately $18,686,000 as of January 31, 2025, compared to approximately $21,362,000 at October 31, 2024[90]. - Cash used in operating activities was approximately $2,904,000 for the three months ended January 31, 2025[91]. - Cash provided by investing activities was approximately $2,703,000, resulting from the maturities of short-term investments of approximately $15,700,000[91]. - The company has approximately $97 million of common stock available for sale under its at-the-market equity program as of January 31, 2025[90]. Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $6,000 to approximately $29,000 for the three months ended January 31, 2025[88].